CORDIS · 241879 · FP7
REBORNE Regenerating Bone defects using New biomedical Engineering approaches
Coordinator: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autografts account for more than 80% of total graft volume. Significant growth opportunities exist for synthetic bone grafts in association with mesenchymal stem cells from autologous or allogenic sources a…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €11.9M awarded to the consortium. The project runs over approximately 5.5 years from 2010-01-01 to 2015-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from FR
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FP7 · €250.0M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · HORIZON · €200.0M
- Biodiversa-plus — The European Biodiversity Partnership101052342 · HORIZON · €105.0M
- OFELIA — Open Fan for Environmental Low Impact of Aviation101102011 · HORIZON · €100.0M
- EPI SGA1 — SGA1 (Specific Grant Agreement 1) OF THE EUROPEAN PROCESSOR INITIATIVE (EPI)826647 · H2020 · €80.0M
- Water4All — Water4All – Water Security for the Planet101060874 · HORIZON · €56.9M
Other FP7 projects
see all →- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- MAAXIMUS — More Affordable Aircraft structure through eXtended, Integrated, and Mature nUmerical Sizing213371 · DE · €40.2M
- LEMCOTEC — Low Emissions Core-Engine Technologies283216 · DE · €40.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-IP funding scheme.
- What is the EU contribution?
- The European Commission contributes €11.9M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR).
- What is the project timeline?
- The project runs from 2010-01-01 to 2015-06-30 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 241879.